Today, we are extremely excited to announce a new partnership with Dyne Therapeutics, an innovative organization whose FORCE™ Platform is working to bring transformational therapies for serious muscle diseases, including […]
View Letter to the Duchenne Community As recently as March 9, CureDuchenne was helping NS Pharma get the word out about their newly launched Expanded Access Program for enabling access […]
THE CURRENT ADVICE FROM THE PROFESSIONAL SOCIETIES IS TO CONTINUE WITH ACE-I AND ARBS. The European Society of Cardiology (ESC) Council on Hypertension announced their stance in a positioning statement […]
As a mom, a family, a friend, an advocate and a community, we know that the spread of the coronavirus disease 2019 (COVID-19) is clearly creating challenging times that call […]
If you or your child is covered by Medicare – Starting on March 6th, Medicare has broadened coverage for telehealth services so that you may be able to access your […]
What you can do, Cares Events, Updates and More With the coronavirus (COVID-19) situation evolving, CureDuchenne is closely monitoring the latest developments using the World Health Organization, Centers for Disease […]
NEWPORT BEACH, Calif., (March 10, 2020) – CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will co-host a free webinar with Pfizer to discuss their […]
3/13/2020: UPDATED ANNOUNCEMENT AVAILABLE HERE » We never want to put anyone from the Duchenne community at risk, and with the statements from the CDC regarding travel risks, especially for persons […]
CureDuchenne congratulates Pfizer on their progress to a Phase III clinical trial for #PF-06939926, its AAV9 mini-dystrophin gene therapy for Duchenne muscular dystrophy. We’re grateful to Pfizer for their dedication […]
